Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis
Top Cited Papers
Open Access
- 31 March 2006
- journal article
- contribution from-the-field
- Published by Wiley in Arthritis Care & Research
- Vol. 55 (2) , 333-337
- https://doi.org/10.1002/art.21841
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Serious Infections Associated with Anticytokine Therapies in the Rheumatic DiseasesJournal of Intensive Care Medicine, 2004
- Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003)Annals of the Rheumatic Diseases, 2003
- Infection after total hip arthroplastyThe Journal of Bone and Joint Surgery. British volume, 2003
- Management of Infection Associated with Prosthetic JointsInfection, 2003
- Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanerceptArthritis & Rheumatism, 2002
- Experience with etanercept in an academic medical center: Are infection rates increased?Arthritis & Rheumatism, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Published by Massachusetts Medical Society ,2001
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- Factors Influencing the Incidence and Outcome of Infection Following Total Joint ArthroplastyClinical Orthopaedics and Related Research, 1984